Recently, higher serum and CSF GFAP were identified in the progressive phase of MS than in RRMS, and these levels correlated with disease severity, MRI lesion count, and clinical disability in MS (Ayrignac et al., 2020). This evidence concerns the gene GFAP and myeloid sarcoma.